RxDoctor Payments Data

Tilemahos Spyratos, DO

Gastroenterology · Olympia Fields, ILNPI 1295055291

Payments from drug & device makers

$8,544in general payments, 2019–2025

Across 432 payments — averaging $19.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Phathom Pharmaceuticals, Inc.$890
  • Ardelyx, Inc.$605
  • Merck$349
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$8,35698%
  • Education$1882%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,544 in reported general payments places this provider in the 75th percentile of 787 gastroenterology providers in Illinois.

See all gastroenterology providers in Illinois

Medicare billing

Part B allowed, 2024
$99,720
Medicare patients
406
Services billed
835

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntyvioVedolizumab14$120,762
LinzessLinaclotide89$95,993
CreonLipase/Protease/Amylase34$85,146
Mesalamine18$15,070
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates134$9,109
MovantikNaloxegol Oxalate13$7,198
Sucralfate14$4,610
Pantoprazole Sodium292$3,850
Omeprazole65$1,551
Azathioprine22$1,347
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl79$1,008
Clarithromycin17$610
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl32$590
Famotidine25$168
Amoxicillin19$101

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$1,750$181,139123 claims
Takeda Pharmaceuticals U.S.A., Inc.Entyvio$1,106$120,76214 claims
Redhill Biopharma Inc.Movantik$49$7,19813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 787 gastroenterology providers in Illinois.

Other gastroenterology in Olympia Fields

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →